



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	BEHAN	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/700,189	04/14/99			

LAURENCE A WEINBERGER
PO BOX 1663 SUITE 103
883 S MATLACK ST
WEST CHESTER PA 19308-0053

HM11/0624

EXAMINER
BASIL N.

ART UNIT	PAPER NUMBER
1646	

06/24/99
DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary	Application No. 09/060,188	Applicant(s) BEHAN et al
	Examiner Nirmal. S. Basi	Group Art Unit 1646

Responsive to communication(s) filed on _____.

This action is **FINAL**.

Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 1 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

Claim(s) 1-44 is/are pending in the application.

Of the above, claim(s) _____ is/are withdrawn from consideration.

Claim(s) _____ is/are allowed.

Claim(s) _____ is/are rejected.

Claim(s) _____ is/are objected to.

Claims 1-44 are subject to restriction or election requirement.

Application Papers

See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

The drawing(s) filed on _____ is/are objected to by the Examiner.

The proposed drawing correction, filed on _____ is approved disapproved.

The specification is objected to by the Examiner.

The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

All Some* None of the CERTIFIED copies of the priority documents have been

received.

received in Application No. (Series Code/Serial Number) _____.

received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____.

Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

Notice of References Cited, PTO-892

Information Disclosure Statement(s), PTO-1449, Paper No(s). _____

Interview Summary, PTO-413

Notice of Draftsperson's Patent Drawing Review, PTO-948

Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Art Unit: 1646

An election to prosecute one of the groups listed I-II must be made. Affirmation of this election must be made by applicant in responding to this Office action.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

Advisory Information

10 Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nirmal Basi whose telephone number is (703) 308-9435. The examiner can normally be reached on Monday-Thursday from 9:00 to 5:30.

15 If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Paula Hutzell, can be reached on (703) 308-4310. The fax phone number for this Group is (703) 308-0294.

Official papers filed by fax should be directed to (703) 308-4242. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

20 Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Nirmal S. Basi
Art Unit 1646
25 June 16, 1999


PAULA K. HUTZELL
SUPERVISORY PATENT EXAMINER

Art Unit: 1646

- I. Claims 1-18, 33-34, 39-40 drawn to method for identifying a candidate compound as
a an inverse agonist, partial agonist and an agonist to an orphan receptor, classified
in class 435, subclass 7.1.
- II. Claims 19-32, 35-38, 41-44 drawn to compounds or pharmaceutical composition
identified by the methods of claims 1-6, 14, 19, 20-25, 33-36 and 39-42, inverse
agonist, partial agonist and an agonist have not been disclosed therefore the class
and subclass can not be determined.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown
to be distinct if either or both of the following can be shown: (1) the process for using the product
as claimed can be practiced with another materially different product or (2) the product as claimed
can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant
case the inverse agonist, partial agonist and an agonist may be used to produce antibodies.

Because these inventions are distinct for the reasons given above and have acquired a separate
status in the art, restriction for examination purposes as indicated is proper. A search of the art for
Inventions I-II would not be co-extensive with each other as shown by their different classifications
(the compounds of Group II would be classified differently than the methods). Because the searches
required for these inventions are not co-extensive an examination of the materially different,
patentably distinct inventions in a single application would constitute a serious burden on the
examiner.

Art Unit: 1646

DETAILED ACTION

1. The Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1646.

5 2. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

10 Applicant must comply with the sequence rules, 37 CFR 1.821 - 1.825 within the statutory period set for response to this office action. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for response beyond the SIX MONTH statutory period.

15 Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121: